The Authorized Generic Playbook: Why Brands Launch Their Own Competition, Even if There is No Competition
The Counterintuitive Move That Makes Perfect Business Sense A brand pharmaceutical company holds an approved drug. No generic competitor has
Insights
Pick the Right FDA Pathway and You Own the Market. Pick the Wrong One and You’re Funding Your Competitor.
A forensic comparison of the 505(b)(2) and 505(j) regulatory strategies that separate profitable pharmaceutical launches from expensive cautionary tales. The
Five Plays That Keep Your Blockbuster Drug Alive After the Patent Clock Runs Out
A forensic guide to pharmaceutical life cycle extension: the IP strategies, regulatory mechanics, and commercial execution frameworks that separate drugs
Five Plays That Keep Your Blockbuster Drug Alive After the Patent Clock Runs Out Read Post »
When Big Pharma Walks Away: What Abandoned Patents Reveal About Pipeline Priorities
Somewhere in the patent office’s public records, there is a graveyard. It has no physical address and no memorial plaques,
When Big Pharma Walks Away: What Abandoned Patents Reveal About Pipeline Priorities Read Post »
Stop AI Hallucinations From Destroying Your Drug Brand Value
Pharmaceutical executives are losing control of their product narratives. While marketing teams focus on search engine optimization and field sales,
Stop AI Hallucinations From Destroying Your Drug Brand Value Read Post »
Know Before the Cliff: How AI and Patent Analytics Let You See Generic Competition Coming
Pfizer’s finance team did not need a news alert to know Lipitor was in trouble. By 2010, the company’s own
Fix Pharma Forecasts: Common Misinterpretations of the FDA Orange Book That Distort Market Forecasts
Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model
A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
Stop Patent Hops: Detecting “Evergreening” Patterns Through Sequential FDA Orange Book Listings
The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of
